Partner & Employee Best Access
First time users must log in to Best Access via the Virtual Environment, not via this link.


Sep 2, 2015

Update in Amgen v. Sandoz

On August 31, 2015, to support the launch of its Zarxio™ (a biosimilar of Amgen's Neupogen® (filigrastim) product), Sandoz filed an opposition to Amgen's emergency motion for injunction pending en banc consideration and review. The opposition can be found here: Sandoz opposition 08-31-2015 — 17703935 v1. Sandoz argues that Amgen's emergency motion should be denied since […]
back to top